Beyond characterizing the inhibition of tumor progression, we also examined the regulatory effects of LRP5-overexpressing osteocyte-derived CM on RANKL-induced osteoclast differentiation and immune cell activation. The gene discussed is LRP5; the disease is neoplasm.